|
CEP290 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.46531700504238E-13 |
| Normal-vs-Stage2 |
1.02570000271029E-08 |
| Normal-vs-Stage3 |
8.88178419700125E-16 |
| Normal-vs-Stage4 |
5.74762459848444E-13 |
| Stage1-vs-Stage2 |
8.284600E-01 |
| Stage1-vs-Stage3 |
1.038420E-01 |
| Stage1-vs-Stage4 |
7.199900E-02 |
| Stage2-vs-Stage3 |
1.633630E-01 |
| Stage2-vs-Stage4 |
1.138760E-01 |
| Stage3-vs-Stage4 |
7.457000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.88498130835069E-15 |
| Normal-vs-AfricanAmerican |
1.71044999999204E-05 |
| Normal-vs-Asian |
1.69350000689406E-09 |
| Caucasian-vs-AfricanAmerican |
5.202000E-01 |
| Caucasian-vs-Asian |
4.894800E-01 |
| AfricanAmerican-vs-Asian |
8.034000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-15 |
| Normal-vs-Female |
1.62547753035369E-12 |
| Male-vs-Female |
9.247200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.6251444634463E-12 |
| Normal-vs-Age(41-60Yrs) |
6.38877839520546E-12 |
| Normal-vs-Age(61-80Yrs) |
3.07265324295258E-12 |
| Normal-vs-Age(81-100Yrs) |
1.194210E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.689200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.935400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.670000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.830400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.869800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.322400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.641400E-03 |
| Classical-VS-Follicular |
3.537600E-01 |
| Classical-VS-Other |
9.719000E-01 |
| Classical-VS-Normal |
6.48809894698843E-11 |
| Tall-VS-Follicular |
1.137760E-02 |
| Tall-VS-Other |
2.087200E-01 |
| Tall-VS-Normal |
6.96220858742436E-13 |
| Follicular-VS-Other |
7.925400E-01 |
| Follicular-VS-Normal |
1.01799999996377E-06 |
| Other-VS-Normal |
4.855000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.33066907387547E-16 |
| Normal-vs-N1 |
7.46229744663651E-11 |
| N0-vs-N1 |
8.417400E-01 |
|
|
